Home/Filings/4/0001209191-20-037031
4//SEC Filing

Frazier Life Sciences IX, L.P. 4

Accession 0001209191-20-037031

CIK 0001783183other

Filed

Jun 15, 8:00 PM ET

Accepted

Jun 16, 5:42 PM ET

Size

16.0 KB

Accession

0001209191-20-037031

Insider Transaction Report

Form 4
Period: 2020-06-12
Transactions
  • Other

    Common Stock

    2020-06-121,456,8545,827,415 total
Holdings
  • Common Stock

    (indirect: See footnote)
    12,596
  • Common Stock

    (indirect: See footnote)
    1
  • Common Stock

    (indirect: See footnote)
    3,912
  • Common Stock

    (indirect: See footnote)
    14,937
Transactions
  • Other

    Common Stock

    2020-06-121,456,8545,827,415 total
Holdings
  • Common Stock

    (indirect: See footnote)
    12,596
  • Common Stock

    (indirect: See footnote)
    3,912
  • Common Stock

    (indirect: See footnote)
    14,937
  • Common Stock

    (indirect: See footnote)
    1
Transactions
  • Other

    Common Stock

    2020-06-121,456,8545,827,415 total
Holdings
  • Common Stock

    (indirect: See footnote)
    14,937
  • Common Stock

    (indirect: See footnote)
    1
  • Common Stock

    (indirect: See footnote)
    12,596
  • Common Stock

    (indirect: See footnote)
    3,912
Transactions
  • Other

    Common Stock

    2020-06-121,456,8545,827,415 total
Holdings
  • Common Stock

    (indirect: See footnote)
    12,596
  • Common Stock

    (indirect: See footnote)
    14,937
  • Common Stock

    (indirect: See footnote)
    1
  • Common Stock

    (indirect: See footnote)
    3,912
Transactions
  • Other

    Common Stock

    2020-06-121,456,8545,827,415 total
Holdings
  • Common Stock

    (indirect: See footnote)
    14,937
  • Common Stock

    (indirect: See footnote)
    3,912
  • Common Stock

    (indirect: See footnote)
    1
  • Common Stock

    (indirect: See footnote)
    12,596
Footnotes (7)
  • [F1]Represents a pro rata distribution in-kind by Frazier Life Sciences IX, L.P. ("FLS IX") to its limited partners for no consideration.
  • [F2]Represents shares held of record by FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F3]Reflects shares of Common Stock received in the distribution in-kind described herein.
  • [F4]Represents shares held of record by FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. These shares were previously held through FLS IX.
  • [F5]Represents shares held directly by Dr. Topper. These shares were previously held through FLS IX.
  • [F6]Represents shares held of record by Topper Group III LLC. Dr. Topper is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC. These shares were previously held through FLS IX.
  • [F7]Represents shares held by The Heron Living Trust 11/30/2004. Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. These shares were previously held through FLS IX.

Issuer

Phathom Pharmaceuticals, Inc.

CIK 0001783183

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001720320

Filing Metadata

Form type
4
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 5:42 PM ET
Size
16.0 KB